Aclidinium Bromide/Formoterol Fumarate

DRUG3 trials

Sponsors

AstraZeneca

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 3

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01437397

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2011-09-30End: 2013-02-28Updated: 2017-03-23

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

CompletedNCT01437540

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2011-09-19End: 2013-04-30Updated: 2017-05-11

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

CompletedNCT01462942

AstraZenecaChronic Obstructive Pulmonary Disease (COPD)

Start: 2011-10-31End: 2013-01-31Updated: 2017-02-15

Related Papers

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD.

2019-12-0614 citations

Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy

2017-09-011 citations

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol

Respiratory Research2017-05-3033 citations

Reduction in clinically important deterioration in COPD with aclidinium/formoterol

2016-09-01

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.

2016-08-2915 citations

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.

2016-05-2317 citations

Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use

Pneumologie2016-02-091 citations

Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity

Pneumologie2016-02-09

S60 Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use: Abstract S60 Table 1

Thorax2015-11-12

Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients

2015-09-013 citations

Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity

2015-09-013 citations

Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD

2015-09-01

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

Respiratory Research2015-08-01114 citations

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

BMC Pulmonary Medicine2014-11-17172 citations

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

2014-10-14106 citations